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General synthesis of metal complexes
[Pt(HCC-bpy)Cl2] (1). A mixture of cis-Dichlorobis(dimethyl sulfoxide)platinum(II) (150 mg, 
35.5 mmol, 1.0 eq.) and 4-ethynyl-2,2'-bipyridine (76.7 mg, 43.0 mmol, 1.2 eq.) was 
dissolved in DMF (10 ml) and stirred overnight at room temperature. Upon addition of water 
(2 ml), a bright yellow precipitate formed. The precipitate was filtered and washed with 
CH3CN (10 ml) and CH3OH (10 ml). The solid was dried under vacuum and used without 
further purification. Yield: 142 mg (90%); 1H NMR (500 MHz, DMSO->G@į = 9.51 (dd, J =
5.84, 1.1 Hz, 1H, HC-11L), 9.49 (d, J = 6.35 Hz, 1H, HC-7L) 8.73 (d, J = 1.6 Hz, 1H, HC-4L), 
8.68 (d, J = 7.95 Hz, 1H, HC-9L), 8.42 (dt, J = 7.95, 1.4 Hz, 1H, HC-10L), 7.91-7.84 (m, 2H,
HC-5L, HC-12L), 5.20 (s, 1H, HC-1L) ppm; 13C NMR (125 MHz, DMSO->G@ į  
156.3, 148.4, 148.1, 140.6, 133.3, 129.5, 128.0, 126.4, 124.6, 90.7, 80.2 ppm, 195Pt (107 
MHz, DMSO-[d6], referred to Na2[PtCl6@į = -2300 ppm; Anal. Calcd. for C12H8Cl2N2Pt: C, 
32.30; H, 1.81; N, 6.28. Found: C, 32.17; H, 1.91; N, 6.40; IR (solid state, KBr, cm-1): Ȟ&Ł&
2113.
[Ru((Et2N)2Bpy)2(HCC-bpy)]Cl3 (2). A mixture of [Ru((Et2N)2Bpy)2Cl2]Cl[1] (250 mg, 0.32 
mmol, 1.0 eq.), 4-ethynyl-2,2'-bipyridine (175 mg, 0.97 mmol, 3.0 eq.) and trimethylamine 
(0.01 ml, 0.14 mmol, 0.5 eq.) was dissolved in CH3OH (20 ml) and heated at reflux under an 
argon atmosphere for 4h. The solution was allowed to cool and the solvent removed by 
rotary evaporation. The crude product (460 mg) was redissolved in the minimum amount of 
CH3CN and purified by column chromatography on silica gel using acetonitrile, water, 
methanol and saturated NaCl (0.6:0.149:0.25:0.1%). The first band to elute (purple) was 
discarded and the second band (deep red) collected. After evaporation of the solvent, the 
solid was redissolved in CH2Cl2 (10 ml) and suction filtered to remove insolubles (presumably 
NaCl). The filtrate was dried under vacuum to yield 233 mg (82%) of the compound 2. 1H
NMR (500 MHz, DMSO-[d6]): į = 8.84 (s, 1H, HC-7L), 8.82 (d, J = 8.0 Hz, 1H, HC-12L), 8.01 
(td, J = 8.0, 1.2 Hz, 1H, HC-11L), 7.87 (m, 2H, HC-9L, HC-4L), 7.58-7.53 (m, 6H, HC-
16/19/34/37L, HC-10L, HC-5L), 7.12 (d, J = 3.3 Hz, 1H, HC-40L), 7.10 (d, J = 3.3 Hz, 1H,
HC-13L), 6.94 (d, J = 6.8 Hz, 1H, HC-31L), 6.85 (d, J = 6.8 Hz, 1H, HC-22L), 6.81 (td, J =
6.8, 2.7 Hz, 2H, HC-14L, HC-39L), 6.63 (m, 2H, HC-21L, HC-32L), 4.90 (s, 1H, HC-1L), 3.56-
3.46 (m, 16H, HC-23/25/27/29/41/43/45/47L), 1.16-1.06 (m, 24H, HC-
24/26/28/30/42/44/46/48L); 13C NMR (125 MHz, DMSO-[d6]): į = 158.3, 157.1, 156.6, 156.5, 
156.2, 156.1, 152.0, 151.9, 151.8, 151.7, 151.0, 150.8, 149.2, 149.0, 148.7, 148.5, 135.5, 
128.8, 127.7, 127.5, 125.8, 124.3, 109.6, 109.4, 105.2, 105.1, 88.2, 80.6, 43.5, 12.0, 11.9;
Anal. Calcd. for C48H60Cl3N10Ru: C, 58.56; H, 6.14; N, 14.23. Found: C, 58.91; H, 6.11; N, 
13.77; HRMS (ESI+): [M]2+ = 439.2020, calculated for C48H60N10Ru1 = 439.2022; IR (solid 
state, KBr, cm-1): Ȟ&Ł&2122.
[Re(HCC-bpy)(CO)2Br2] (3). A mixture of (Et4N)2[Re(CO)2Br4][2] (100 mg, 0.12 mmol, 1.0 
eq.) and 4-ethynyl-2,2'-bipyridine (27 mg, 0.15 mmol, 1.25 eq.) was dissolved in DME (10 ml) 
and stirred during 4h at 60 °C. The solution was dried under vacuum, dissolved in a minimum 
amount of CHCl3 and purified by column chromatography on silica gel using CHCl3/Ethanol 
(200:1). The first band to elute (dark brown) was determined to be complex 3. Yield: 43 mg 
(61%); NMR spectrum is not reported because the compound is paramagnetic; Anal. Calcd. 
for C14H8Br2N2O2Re: C, 28.88; H, 1.38; N, 4.81. Found: C, 28.71; H, 1.28; N, 4.81; MS
MALDI-TOF (POS, DCTB): [M]+ = 580.8433, calculated for C14H8Br2N2O2Re = 580.8510; IR 
(solid state, KBr, cm-1): Ȟ&Ł&2119, ȞC=O 1994, 1842.
[Ru(HCC-bpy)(bpy)2]Cl2 (4). Complex 4 was obtained via anion metathesis starting from 
[Ru(HCC-bpy)(bpy)2](PF6)2.[3] The latter was dissolved in acetone and an aqueous solution of 




Characterization of the vitamin B12 derivatives
B12-bpy. Red powder; Yield: 52.8 mg (78%); 1H NMR (500 MHz, MeOD-[d4]): į = 8.73 (d, J = 4.6 
Hz, 1H, HC-9L), 8.41 (d, J = 5.7 Hz, 1H, HC-5L), 8.23 (d, J = 8.0 Hz, 1H, HC-12L), 8.07 (t, J = 8 
Hz, 1H, HC-11L), 7.84 (s, 1H, HC-7L), 7.60 (dd, J = 5.2, 2.0 Hz, 1H, HC-10L), 7.24 (s, 1H, HC-
7N), 7.22 (s, 1H, HC-2N), 7.07 (d, J = 5.7 Hz, 1H, HC-4L), 6.62 (s, 1H, HC-4N), 6.27 (d, J = 3.2 
Hz, 1H, HC-1R), 6.03 (s, 1H, HC-10), 4.72-4.63 (m, 1H,HC-3R), 4.55 (d, J = 9 Hz, 1H, HC-3), 
4.38-4.28 (m, 1H, HC-19), 4.20 (t, J = 3.6 Hz, 1H, HC-176), 4.13-4.08 (m, 1H, HC-2R), 3.92 (dd, 
J = 9.5, 3.2, 1H, HC-4R), 3.78-3.64 (m, 3H, HbC-5R, HaC-5R, HbC-175), 3.27 (m, 2H, HC-8, HC-
13), 2.88-2.80 (m, 2H, HaC-175, HC-18), 2.66-2.62 (m, 1H, HC-8), 2.6 (s, 3H, H3C-51), 2.60-5.58 
(m, 3H, H3C-151), 2.57 (m, 1H, HbC-132), 2.56-2.53 (m, 2H, H2C-32), 2.52-2.47 (m, 3H, HbC-21, 
HaC-132 HbC-71), 2.45-2.36 (m, 2H, HbC-181, HaC-21), 2.29 (s, 3H, H3C-11N), 2.27 (s, 3H, H3C-
10N), 2.24-2.16 (m, 1H, HaC-171), 2.10-2.01 (m, 3H, HaC-181, HbC-131, HaC-71), 2.00-1.96 (m, 
1H, HbC-81), 1.95-1.87 (m, 3H, HbC-31, HaC-31, HaC-131), 1.85 (s, 3H, H3C-7A), 1.83-1.78 (m, 
1H, HaC-172), 1.77 (m, 1H, HbC-82), 1.46 (s, 3H, H3C-12A), 1.37 (s, 3H, H3C-2A), 1.36 (m, 1H, 
Ha-82), 1.32 (s, 3H, H3C-17B), 1.31 (m, 1H, HaC-81), 1.25 (d, J = 6.25 Hz, 3H, H3C-177), 1.15 (s, 
3H, H3C-12B), 0.51 (s, 3H, H3C-1A) ppm; 13C NMR (125 MHz, MeOD-[d4]): į = 180.2, 178.7, 
177.7, 177.3, 176.8, 176.5, 175.8, 175.5, 174.5, 174.4, 166.6, 166.4, 150.1, 146.4, 143.7, 140.3, 
138.7, 135.2, 131.6, 128.0, 127.1, 125.2, 123.4, 118.4, 112.2, 108.1, 104.9, 102.3, 95.5, 87.9, 
86.3, 83.6, 75.9, 75.6, 73.8, 73.7, 70.8, 62.7, 60.0, 57.1, 56.3, 55.1, 52.1, 46.7, 43.9, 43.9, 43.8, 
40.1, 36.4, 35.3, 33.4, 33.1, 32.9, 32.5, 32.0, 29.6, 27.5, 27.4, 20.9, 20.8, 20.3, 20.1, 20.0, 17.6, 
17.2, 16.4, 16.1 ppm; HRMS (ESI+): [M+Na]+ = 1530.6148, calculated for 
C74H95Cl2Co1N15O14P1Na2 = 1530.6144; IR (solid state, KBr, cm-1): Ȟ&Ł&2124.
B12-1. Red powder; Yield: 52.7 mg (61%); 1H NMR (500 MHz, MeOD-[d4]): į = 8.88 (d, J = 5.0 
Hz, 1H, HC-9L), 8.50 (d, J = 5.0 Hz, 1H, HC-5L), 8.25-8.15 (m, 2H, HC-11, HC-12L), 7.60 (s, 1H,
HC-7L), 7.49 (m, 1H, HC-10L), 7.25 (s, 1H, HC-7N), 7.23 (s, 1H, HC-2N), 6.86 (d, J = 5.0 Hz, 1H,
HC-4L), 6.65 (s, 1H, HC-4N), 6.28 (d, J = 2.5 Hz, 1H, HC-1R), 6.0 (s, 1H, HC-10), 4.70-4.63 (m, 
1H, HC-3R), 4.57 (s, 1H, HC-3), 4.39 (d, J = 11.3 Hz, 1H, HC-19), 4.36-4.29 (m, 1H, HC-176), 
4.22-4.18 (m, 1H, HC-2R), 4.14-4.08 (m, 1H, HC-4R), 3.92 (d, J = 11.3 Hz, 1H, HbC-5R), 3.80-
3.71 (m, 2H, HaC-5R, HbC-175), 3.67 (m, 2H, HC-8, HC-13), 2.83 (m, 2H, HaC-175, HC-18), 2.73 
(m, 3H, H3C-51), 2.71-2.67 (m, 3H, H3C-151), 2.61 (s, 3H, HbC-21, HaC-132 HbC-71), 2.57-2.53 
(m, 1H, HbC-132), 2.53-2.48 (m, 2H, H2C-32), 2.31 (s, 3H, H3C-11N), 2.29 (s, 3H, H3C-10N), 2.20 
(t, J = 12.9 Hz, 1H, HaC-171), 2.13-2.04 (m, 3H, HaC-181, HbC-131, HaC-71), 2.03-1.94 (m, 4H,
HbC-81, HbC-31, HaC-31, HaC-131), 1.90 (s, 3H, H3C-7A), 1.86-1.80 (m, 1H, HaC-172), 1.78-1.71 
(m, 1H, HbC-82), 1.47 (s, 3H, H3C-12A), 1.45 (s, 3H, H3C-2A), 1.37 (s, 3H, H3C-17B), 1.28 (s, 1H, 
HaC-81), 1.25 (d, J = 6.25 Hz, 3H, H3C-177), 1.12 (s, 3H, , H3C-12B), 0.51 (s, 3H, H3C-1A) ppm; 
13C NMR (125 MHz, MeOD-[d4]): į = 180.3, 178.8, 177.8, 177.3, 176.9, 176.4, 176.3, 175.9, 
174.9, 174.6, 174.5, 166.5, 166.4, 158.4, 158.4, 157.9, 149.2, 148.5, 143.8, 141.6, 139.1, 138.7, 
135.1, 133.6, 131.6, 129.3, 128.1, 127.2, 126.2, 118.4, 112.2, 108.0, 105.0, 101.9, 95.3, 87.9, 
86.4, 83.6, 83.5, 76.0, 75.6, 73.6, 73.5, 70.8, 62.8, 60.3, 56.9, 56.3, 55.0, 52.0, 46.7, 45.1, 43.5, 
40.2, 36.6, 35.4, 33.7, 33.2, 33.1, 33.0, 32.3, 30.7, 29.7, 27.5, 20.9, 20.6, 20.4, 20.3, 20.2, 20.1, 
20.0, 18.2, 17.7, 16.8, 16.4 ppm, 195Pt (107 MHz, DMSO-[d6], referred to Na2[PtCl6]): į = -2311 
ppm; HRMS (ESI+): [M+2Na]2+ = 909.7522, calculated for C74H95Cl2Co1N15O14P1Pt1Na2 =
909.7533; IR (solid state, KBr, cm-1): Ȟ&Ł&2123.
B12-2. The following modification was applied to the general procedure: the first crude precipitate 
was dissolved in CH2Cl2 and filtered to remove the excess of 2. The remaining mixture was then 
purified as described above. Deep red powder; Yield: 71.2 mg (73%); 1H NMR (500 MHz, MeOD-
[d4]): į = 8.31 (t, J = 8.25 Hz, 1H, HC-9L), 7.94 (br d, J = 5.15 Hz, 1H, HC-12L), 7.90 (dd, J = 7.2, 
6.0 Hz, 1H, HC-10L), 7.78 (d, J = 7Hz, 1H, HC-5L), 7.67 (dd, J = 4, 1.65 Hz, 1H, HC-7L), 7.57-
7.59 (m, 4H, HC-16/19/34/37L), 7.41-7.34 (m, 1H, HC-11L), 7.25-7.18 (m, 4H, HC-7N, HC-2N, 
HC-13/40L), 6.96-6.88 (m, 2H, HC-22/31L), 6.79 (d, J = 6 Hz, 1H, HC-4L), 6.68-6.20 (m, 2H, HC-
14/39L), 6.61 (s, 1H, HC-4N), 6.56-6.47 (m, 2H, HC-21/32L), 6.27 (d, J = 3 Hz, 1H, HC-1R), 6.01 
(d, J = 7.30 Hz, 1H, HC-10), 4.70 (br s, 1H, HC-3R), 4.56-4.49 (m, 1H, HC-3), 4.40-4.27 (m, 2H, 
HC-19, HC-176), 4.23-4.18 (m, 1H, HC-2R), 4.13-4.07 (m, 1H, HC-4R), 3.92 (br d, J = 11 Hz, 
S5 
 
1H, HbC-5R), 3.75 (br d, J = 11 Hz, 2H, HaC-5R, HbC-175), 3.69-3.62 (m, 2H, HC-8, HC-13), 
3.59-3.49 (m, 16H, H2C-23/25/27/29/41/43/45/47L), 2.88-2.77 (m, 2H, HaC-175, HC-18), 2.64-
2.60 (m, 3H, H3C-51), 2.59 (br s, 3H, H3C-151), 2.58-2.56 (m, 1H, HbC-132), 2.54 (s, 3H, HbC-21, 
HaC-132 HbC-71), 2.50-2.34 (m, 3H, HbC-132, H2C-32), 2.28 (s, 3H, H3C-11N), 2.27 (s, 3H, H3C-
10N), 2.18 (t, J = 13 Hz, 1H, HaC-171), 2.09-1.96 (m, 4H, HaC-181, HbC-131, HaC-71, HbC-81), 
1.95-1.87 (m, 4H, HbC-31, HaC-31, HbC-31, HaC-31), 1.84 (s, 3H, H3C-7A), 1.82-1.76 (m, 2H, 
HaC-172), 1.76-1.67 (m, 1H, HbC-82), 1.45 (d, J = 3.85 Hz, 3H, H3C-12A), 1.36 (s, 3H, H3C-12A), 
1.27 (d, J = 10.4 Hz, 3H, H3C-17B), 1.26 (s, 1H, HaC-81), 1.25 (d, J = 6.45 Hz, 3H, H3C-177), 
1.23-1.16 (m, 24H, H3C-24/26/28/30/42/44/46/48L), 1.12 (d, J = 12.4 Hz, 3H, H3C-12B), 0.49 (s, 
3H, H3C-1A) ppm. 13C NMR (125 MHz, MeOD-[d4]): į = 180.2, 178.6, 177.8, 177.3, 176.8, 176.4, 
176.1, 175.7, 174.8, 174.7, 174.4, 174.2, 166.5, 166.2, 166.1, 159.3, 159.2, 158.7, 158.6, 158.3, 
153.9, 153.8, 153.7, 152.4, 151.7, 150.5, 150.4, 143.7, 138.7, 136.5, 135.2, 134.2, 133.4, 131.6, 
129.3, 127.9, 125.6, 124.6, 124.5, 118.4, 112.2, 110.4, 110.3, 106.4, 106.3, 106.2, 104.9, 101.2, 
95.5, 87.9, 86.3, 75.7, 75.6, 73.8, 70.8, 62.8, 60.6, 57.1, 56.3, 54.9, 52.2, 52.1, 46.7, 45.2, 44.2, 
40.1, 36.5, 35.3, 33.4, 33.0, 32.9, 32.6, 32.1, 32.0, 29.7, 27.4, 27.3, 20.9, 20.7, 20.3, 20.2, 20.1, 
20.0, 17.7, 17.3, 16.4, 16.2, 12.4, 12.3  ppm; HRMS (ESI+): [M]2+ = 1102.9715, calculated for 
C110H147Co1N23O14P1Ru1 = 1102.9815; IR (solid state, KBr, cm-1): Ȟ&Ł&2123.
B12-3. Red powder; Yield: 65.9 mg (78%); NMR spectrum is not reported because 
the compound is paramagnetic; HRMS (ESI+): [M+Na]+ = 1933.3912, calculated for C76H95Br2
Co1N15O16P1Re1Na1 = 1933.3953; IR (solid state, KBr, cm-1): Ȟ&Ł&2122, ȞC=O 1999, 1869.
B12-4-CBC. The rhodamine labeled vitamin B12 (CBC, 10 mg) previously described[4] was reacted 
with 4 and purified similarly as for the other derivatives. Red powder; Yield: 13.9 mg (72%); 1H
NMR (500 MHz, MeOD-[d4]): į = 8.69-8.63 (m, 4H, HC-13/22/31/40L), 8.48 (d, J = 8.4 Hz, 1H, 
HC-9L), 8.41 (d, J = 8.2 Hz, 1H, HC-3Rh), 8.20 (dd, J = 8.25, 1.73 Hz, 1H, HC-4Rh), 8.12-8.05 
(m, 5H, HC-12L, HC-16/19/34/37L), 7.93 (d, J = 1.25 Hz,1H, HC-7L), 7.77 (d, J = 1.8 Hz, 1H, HC-
6Rh), 7.76-7.68 (m, 5H, HC-10L, HC-15/20/33/38L), 7.48-7.40 (m, 6H, HC-5/11L, HC-
14/21/32/39L), 7.20 (s, 1H, HC-7N), 7.19 (s, 1H, HC-2N), 6.94 (d, J = 1.65 Hz, 2H, HC-11/26Rh), 
6.87 (br s, 2H, HC-17/20Rh), 6.80 (m, 1H, HC-4L), 6.59 (s, 1H, HC-4N), 6.19 (d, J = 2.9 Hz, 1H,
HC-1R), 5.98  (d, J = 6.6 Hz, 1H, HC-10), 4.85-4.80 (m, 1H, HC-3R), 4.62 (d, J = 11.6 Hz, 1H, 
HC-3), 4.50 (t, J = 6.4 Hz, 1H, HC-19), 4.39-4.32 (m, 1H, HC-176), 4.27 (d, J = 10.5 Hz, 1H, HC-
2R), 4.20 (m, 2H, HC-4R, HbC-5R), 4.14 (d, J = 11.6 Hz, 1H, HaC-5R), 3.68-3.50 (m, 15H, HbC-
175, HC-8, HC-13, HC-T5,7,8,10,11,13), 3.50-3.40 (m, 6H, T4,5,13,14), 3.18-3.08 (m, 4H, T3,15), 2.91 
(dd, J = 8.30, 5.35 Hz, 1H, HaC-175), 2.84-2.76 (m, 1H, HC-18), 2.65-2.34 (m, 15H, H3C-51, H3C-
151, HbC-21, HaC-132 HbC-71, HbC-132, H2C-32, H3C-16/23Rh), 2.26 (m, 6H, H3C-11N, H3C-
10N), 2.13 (m, 5H, HaC-181, HbC-131, HaC-71, HC-15/22Rh), 2.08-1.78 (m, 16H, HaC-171, HaC-
181, HbC-131, HaC-71, HbC-81, H3C-7A, HaC-172, HbC-82, HC-13/25Rh), 1.74-1.64 (m, 3H, HbC-
31, HaC-31, HaC-131), 1.44 (d, J = 3.35 Hz, 3H, H3C-12A), 1.39-1.32 (m, 7H, H3C-2A, H3C-17B, 
HaC-81), 1.26 (d, J = 10.0 Hz, 3H, H3C-177), 1.10 (d, J = 15 Hz, 3H, H3C-12B), 0.5 (s, 3H, H3C-
1A) ppm. 13C NMR (125 MHz, MeOD-[d4]): į = 180.2, 178.6, 178.5, 177.3, 176.8, 176.4, 176.0, 
175.7, 174.6, 174.3, 174.2, 167.9, 167.5, 166.5, 166.3, 161.8, 161.4, 159.2, 158.9, 158.6, 158.5, 
158.2, 158.0, 157.7, 152.6, 152.5, 152.4, 152.3, 152.2, 151.8, 151.7, 143.5, 139.5, 139.2, 138.6, 
136.9, 136.6, 135.9, 135.3, 134.7, 133.9, 133.5, 132.9, 131.5, 130.2, 130.0, 128.9, 126.9, 126.4, 
126.4, 125.6, 126.5, 118.5, 114.8, 104.9, 101.2, 95.4, 94.9, 88.1, 86.3, 81.1, 73.6, 71.3, 71.2, 
71.1, 70.6, 76.3, 69.6, 63.9, 59.9, 57.0, 56.0, 54.9, 52.1, 52.1, 40.1, 39.4, 39.1, 39.0, 36.4, 35.1, 
33.2, 33.0, 32.7, 32.5, 32.2, 31.0, 30.2, 29.6, 27.4, 20.9, 20.8, 20.5, 20.4, 20.1, 20.0, 17.7, 17.6, 
17.3, 16.4, 16.20, 14.0 ppm; HRMS (ESI+): [M]2+ = 1304.5040, calculated for 
C132H157Co1N23O22P1Ru1 = 1304.5013; IR (solid state, KBr, cm-1): Ȟ&Ł&2123.
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Figure S1. Atom numbering used for derivatives B12-bpy/1/2/4-CBC
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Figure S2. 500 MHz 1H-NMR of complex 1 (in DMSO-d6, ގ= solvent signal)




Figure S4. 500 MHz 1H-NMR of derivative B12-bpy (in MeOD-d4,ގ= solvent signal) 
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Figure S5. 500 MHz 1H-NMR of derivative B12-1 (in MeOD-d4, ގ= solvent signal)
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Figure S7. 500 MHz 1H-NMR of derivative B12-4-CBC (in MeOD-d4, ގ= solvent signal) 
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Figure S8. Normalized UV-Vis spectra of A) complex 1 and derivative B12-1; B) complex 2
and derivative B12-2; C) complex 3 and derivative B12-3.
Figure S9. UV-Vis and emission spectra of B12-4-CBC, complex 4 and of CBC.
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Figure S10. X-ray data-based MM model of B12-1. Crystals were obtained by slow 
evaporation of water/methanol solution. Unfortunately, due to twinning, the structure of the 
derivative was only partially solved. As it appears in the figure, the bipyridine and 
dimethylbenzamidazole moiety are almost completely eclipsed with a measured 6.4° twist 
angle between their respective planes. 
Figure S11. Left: Low temperature (4 °C) incubation (1h) of B12-4-CBC with MCF7 cells and, 
right: Incubation (1h) at 37 °C of B12-4-CBC with the same cell line. Both Rho and Ru signals 
of the probe are overlapped in the corresponding brightfield image.
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Figure S12. Co-localization images of lysotracker (LTB) and B12-4-CBC in MCF7 cells after 
1h of incubation at 37 °C. A) Brightfield, B) Lysotracker, C) B12-4-CBC (Overlap of the Rho 
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